Allogeneic stem cell transplantation

K. Sawafuji, Shinichiro Okamoto

Research output: Contribution to journalArticle

Abstract

Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.

Original languageEnglish
Pages (from-to)2375-2382
Number of pages8
JournalNippon rinsho. Japanese journal of clinical medicine
Volume59
Issue number12
Publication statusPublished - 2001 Dec

Fingerprint

Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tissue Donors
Unrelated Donors
Interferon-alpha
Protein-Tyrosine Kinases
Leukocytes
Transplantation
Odds Ratio
Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Allogeneic stem cell transplantation. / Sawafuji, K.; Okamoto, Shinichiro.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 59, No. 12, 12.2001, p. 2375-2382.

Research output: Contribution to journalArticle

@article{c1e9eaf58d25476dab2394dd31f22138,
title = "Allogeneic stem cell transplantation",
abstract = "Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.",
author = "K. Sawafuji and Shinichiro Okamoto",
year = "2001",
month = "12",
language = "English",
volume = "59",
pages = "2375--2382",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "12",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation

AU - Sawafuji, K.

AU - Okamoto, Shinichiro

PY - 2001/12

Y1 - 2001/12

N2 - Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.

AB - Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=0035650847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035650847&partnerID=8YFLogxK

M3 - Article

C2 - 11766342

AN - SCOPUS:0035650847

VL - 59

SP - 2375

EP - 2382

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 12

ER -